Hain Lifescience GmbH
Hain Lifescience GmbH is medium-sized company based in Nehren in the South of Germany. The company was founded by the brothers David and Tobias Hain in 1986 and develops, manufactures and distributes molecular genetic diagnostic test systems and instruments for laboratories worldwide. With these tests systems definite statements can be made, for example about the presence of hereditary diseases or the presence of pathogenic bacteria which can cause serious diseases such as tuberculosis or hospital-acquired infections. More than 100 employees work at the headquarter in Nehren. Furthermore, the company has subsidiaries in Spain, France and United Kingdom, South and West Africa as well as a worldwide distribution network.
Bruker Announces Agreement to Acquire Majority in Infectious Disease-focused Molecular Diagnostics (MDx) Company Hain Lifescience GmbH
Press release by FIND:
Companion diagnostics allow for rapid and reliable testing for fluoroquinolone, second-line injectable drugs and isoniazid resistance
Geneva, Switzerland – 11 October 2017 – One of the targets of the United Nations’ Sustainable Development Goals for 2030 is to end the tuberculosis (TB) epidemic, which demands a global effort to tackle the rise of multi-drug resistant TB (MDR TB) and extensively drug-resistant TB (XDR-TB). MDR-TB is TB that is resistant to the first-line drugs isoniazid (INH) and rifampicin (RIF), and XDR-TB is MDR-TB that has developed additional resistance to a fluoroquinolone and any of the injectable compounds used.
Please follow this link to the FIND website in order to read the above mentioned press release:
Hain Lifescience: Rapid, Comprehensive Diagnosis of MDR-TB
Increasing antibiotic resistance requires rapid and comprehensive diagnosis. The new PCR-based FluoroType MTBDR test identifies tuberculosis (TB) pathogens as well as important antibiotic resistance characteristics within three hours. The technology was invented at Brandeis University (USA) and further developed into an in vitro diagnostic test by Hain Lifescience.
WHO recommends rapid test for extensively resistant tuberculosis
On 12 May 2016 the WHO published a recommendation for the rapid tuberculosis test from the company Hain Lifescience GmbH. This facilitates faster detection of resistant TB pathogens, and timely, individual adjustment of patients' medication. It also increases the chances of successful treatment.
View / Download PDF
Contact Hain Lifescience